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Based on the Medical Research Council study, Brown and Brown hypothesized in 1986 that
angiotensin II could protect against strokes by causing vasoconstriction of the proximal
cerebral arteries, thereby preventing Charcot-Bouchard aneurysms from rupturing. In light of
this hypothesis, we evaluated the cerebroprotective effects of various drug classes in recent
double-blinded, prospective, randomized trials, such as SHEP, PATS, CAPPP, HOPE,
PROGRESS, INSIGHT, NORDIL, LIFE, SCOPE, ANBP2, and ALLHAT. Drugs that
activate the AT2 receptors, such as diuretics, calcium antagonists, and angiotensin receptor
blockers (ARBs), were consistently more beneficial for stroke reduction than drugs devoid of
such activation, such as beta-blockers and angiotensin-converting enzyme (ACE) inhibitors,
despite an equal fall in arterial pressure (at least in patients with a low incidence of cardiac
complications). These clinical and epidemiologic observations are supported by experimental
data documenting greater cerebroprotection with ARBs (which increase angiotensin II levels
and stimulate the AT2 receptors) than with ACE inhibitors. Stroke is the most devastating
consequence of hypertensive cardiovascular disease, and our hypothesis of cerebroprotection
by AT2 receptor activation should be tested by a head-to-head comparison of an ARB with
an ACE inhibitor. (J Am Coll Cardiol 2004;43:1343–7) © 2004 by the American College
of Cardiology FoundationH
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sn 1986, Brown and Brown (1) put forth the provocative
ypothesis that angiotensin II could have some cerebropro-
ective effects. The hypothesis was based on findings of the
rst Medical Research Council (MRC) study (2) in which,
hile achieving quite similar decreases in arterial pressure,
iuretics reduced the relative risk of stroke 2.4 times better
han beta-blockers. However, the suggestion that one of the
ost powerful vasoconstrictors, such as angiotensin II,
eemed to be vasculotoxic, could have a protective effect in
he brain seemed extremely farfetched and did not pass
uster in the scientific community. Moreover, all subse-
uent randomized trials in hypertension, until recently, were
iuretic-based and did not allow this hypothesis to be
ested.
o diuretics have a specific cerebroprotective effect?
ver since the Veterans Administration trials (3,4), we have
nown that antihypertensive therapy with diuretics was
xtremely efficacious in reducing the rate of strokes. The
ommon clinical contention was to ascribe this stroke
eduction to diuretics’ powerful lowering of systolic blood
ressure (SBP), as observed, for instance, in the Systolic
ypertension in the Elderly Program (SHEP) study (5).
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eceived grants from pharmaceutical companies, including but not limited to: Merck,
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Manuscript received May 9, 2003; revised manuscript received September 19, 2003,eccepted October 27, 2003.owever, in most studies (2,5–13), a better stroke reduction
as achieved with diuretics than with other antihypertensive
rugs, such as beta-blockers and angiotensin-converting
nzyme (ACE) inhibitors, despite similar reductions in
lood pressure (BP) (Table 1).
The Post-stroke Antihypertensive Treatment Study
PATS) (6) and the Perindopril Protection Against Recur-
ent Stroke (PROGRESS) study (7) are a case in point.
lthough SBP was lowered to the same extent (5 mm Hg)
y monotherapy with both a diuretic or ACE inhibitor,
espectively, a meager 5% reduction of strokes was seen with
erindopril in PROGRESS, whereas a highly significant
eduction of strokes (29%) resulted with indapamide in
ATS. The addition of a diuretic to an ACE inhibitor in
ROGRESS resulted in a dramatic improvement in stroke
eduction, from 5% to 43% for only a 7-mm Hg additional
all in SBP. According to the PROGRESS investigators, a
0-mm Hg SBP fall is expected to decrease the risk of
troke recurrence by only 28% in this population.
iuretics in combination therapy. Not only were diuret-
cs in monotherapy superior to other antihypertensive drugs
or stroke prevention but also a similar phenomenon could
e observed when the stroke risk reduction against placebo
as compared between diuretic monotherapy and combina-
ion therapy. In both MRC studies (2,8), stroke prevention
as the lowest with beta-blocker monotherapy and the
ighest with diuretic monotherapy. Whenever a beta-
locker was added to the diuretic, the efficacy diminished.
n the SHEP study (14), patients receiving a combination of
beta-blocker with a diuretic had a 34% higher risk of
troke than those receiving diuretic monotherapy, despite
qual BP control. In the study by Klungel et al. (15), all
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Cerebroprotection Mediated by AT2 Receptors April 21, 2004:1343–7hiazide combinations (beta-blocker, calcium antagonist,
CE inhibitors) decreased the stroke risk more than non-
hiazide combinations. With thiazide monotherapy, the
troke risk was more than twice lower than that with a
on-thiazide combination.
eta-blockers. Beta-blockers in monotherapy or in com-
ination are remarkably ineffective in reducing the risk of
troke. In the MRC study of the elderly (8), despite the fall
n BP, strokes were not significantly reduced by atenolol-
ased therapy compared with placebo. Similarly, in the
utch Transient Ischemic Attack (TIA) trial (16) of pa-
ients with manifest cerebrovascular disease, atenolol, de-
pite lowering BP, reduced the risk of stroke no better than
lacebo. Finally, in the Scandinavian trial (17), no cerebro-
rotective effects of atenolol were documented. Thus, three
ndependent trials failed to document any benefits of beta-
lockade with regard to stroke reduction, despite a signifi-
ant fall in BP.
alcium antagonists. Ever since the Systolic Hyperten-
ion in Europe (Syst-Eur) trial (18), calcium antagonists
ave been known to reduce stroke rates. When the cerebro-
rotective effects of diuretics were compared with long-
cting dihydropyridine calcium antagonists, there seemed to
e little, if any, difference. In the International Nifedipine-
ITS Study: Intervention as a Goal in Hypertension
reatment (INSIGHT) study (19), in which BP was
owered to the same extent in both treatment arms, the
eduction of strokes with the nifedipine was slightly though
ot significantly better. In the Antihypertensive and Lipid-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ALLHAT  Antihypertensive and Lipid-Lowering
treatment to prevent Heart Attack Trial
ANBP2  Second Australian National Blood
Pressure study
ARB  angiotensin II receptor blocker
BP  blood pressure
CAPPP  CAPtopril Prevention Project
HOPE  Heart Outcomes Prevention Evaluation
study
INSIGHT  International Nifedipine-GITS Study:
Intervention as a Goal in Hypertension
Treatment
LIFE  Losartan Intervention For Endpoint
study
MRC  Medical Research Council
NORDIL  NORdic DILtiazem study
PATS  Post-stroke Antihypertensive Treatment
Study
PROGRESS  Perindopril Protection Against
Recurrent Stroke
SBP  systolic blood pressure
SCOPE  Study on COgnition and Prognosis in
the Elderly study
SHEP  Systolic Hypertension in the Elderly
Programowering treatment to prevent Heart Attack Trial (ALL- tAT) (11,13), the best stroke reduction was achieved by
mlodipine. Chlorthalidone was not significantly inferior to
mlodipine, but patients taking lisinopril and doxazosin did
ignificantly worse. In the European Lacidipine Study on
therosclerosis (ELSA) study (20), the long-acting dihy-
ropyridine lacidipine, compared with atenolol, decreased
he risk of stroke by 36%, but this decrease failed to reach
ignificance because of the low power (only 23 strokes were
bserved). In the NORdic DILtiazem (NORDIL) study
21), even though BP was lowered somewhat less, 20%
reater cerebroprotection was achieved by diltiazem than by
onventional therapy (diuretics and beta-blockers). Prospec-
ive studies (13,19–22) that compared calcium antagonists
nd diuretics with regard to stroke outcome are shown in
able 2.
ngiotensin II receptor blockers (ARBs). In the Losar-
an Intervention For Endpoint (LIFE) study (23) of hyper-
ensive patients with left ventricular hypertrophy, losartan
educed the risk of stroke better than atenolol. The differ-
nce was particularly pronounced in patients with isolated
ystolic hypertension (24), where losartan achieved an im-
ressive 40% stroke reduction. In the Study on Cognition
nd Prognosis in the Elderly (SCOPE), candesartan re-
uced the non-fatal stroke rate by 28% compared with the
ontrol group (12). However, there was a 3.2/1.6-mm Hg
ifference in BP, favoring candesartan. In the subgroup with
solated systolic hypertension, the benefits of ARBs were
ven more pronounced. The recent publication of the Acute
andesartan Cilexetil Therapy in Stroke Survivors (AC-
ESS) pilot trial (25) further supports the BP-independent
erebroprotective effect of ARBs.
ngiotensin-converting enzyme inhibitors. As discussed
arlier, in PROGRESS (7) and ALLHAT (11,13), ACE
nhibitors were not very efficacious in reducing the risk of
troke. The same is true for CAPtopril Prevention Project
CAPPP) trial (9), in which captopril was even associated
ith a 43% greater stroke risk in the on-treatment analysis
ompared with conventional treatment based on thiazides
nd/or beta-blockers; however, SBP was 3 mm Hg higher in
he captopril arm. The exception to the rule seems to be the
eart Outcomes Prevention Evaluation (HOPE) study
10), in which a 32% reduction of strokes was documented
n patients taking ramipril compared with those receiving
lacebo. We should consider, however, that the HOPE
tudy population was unique in that all patients had vascular
isease and more than 80% had coronary heart disease. Not
urprising, the incidence of cardiac complications, such as
yocardial infarction and heart failure, exceeded that of
troke by five-fold. Cardiac complications are a well-known
isk factor for strokes (26). However, although strokes in
ncomplicated hypertension are most often lacunar or
emorrhagic and closely related to small cerebral arterial
isease (27), strokes associated with heart and large-vessel
isease are most often embolic or related to plaque desta-
ilization. Because ramipril in the HOPE study prevented
hree times more cardiac events than strokes, it is very likely
t
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April 21, 2004:1343–7 Cerebroprotection Mediated by AT2 Receptorshat it diminished the stroke risk predominantly by reducing
ardiac complications and preventing plaque destabilization
28–30). This indirect stroke prevention by reducing cardiac
omplications may also mitigate the superiority of angio-
able 1. Prospective Studies Showing Superior Stroke Protection
reatment
Study
(Reference No.) Year
No. of
Patients Type of Patients
Follow
(yrs
RC (2) 1985 17,354 Hypertensive 5.5
HEP (5) 1991 4,736 ISH in elderly 4.5
RC (8) 1992 4,396 Elderly and hypertensive 5.8
ATS (6) 1995 5,665 Post-stroke 3
APPP (9) 1999 10,985 Hypertensive 6.1
OPE (10) 2000 9,297 80% with coronary heart
disease
1.5
LLHAT (11) 2000 24,335 Hypertensive, 25% with
coronary heart disease
4
ROGRESS (7) 2001 6,105 Post-stroke 4
COPE (12) 2002 4,937 Hypertensive and elderly 5
LLHAT (13) 2002 24,309 Hypertensive 4.9
CE  angiotensin-converting enzyme; ALLHAT  Antihypertensive and Lipid
APtopril Prevention Project; HOPEHeart Outcome Prevention Evaluation; ISH
ntihypertensive Treatment Study; PROGRESS Perindopril Protection Against R
Systolic Hypertension in the Elderly Program.
able 2. Prospective Studies Comparing Calcium Antagonists an
Study
(Reference No.) Year
No. of
Patients
Type of
Patients
Follow-Up
(yrs)
NSIGHT (19) 2000 6,321 Hypertensive 4 Ni
ORDIL (21) 2000 10,881 Hypertensive 7 Sh
b
LSA (20) 2002 2,334 Hypertensive 4 Lo
a
LLHAT (13) 2002 24,303 Hypertensive 4.9 Ch
ONVINCE (22) 2003 16,602 Hypertensive 3 Lo
t
LLHAT  Antihypertensive and Lipid-Lowering treatment to prevent Heart Atta
Controlled ONset Verapamil Investigation of Cardiovascular Endpoints; ELSA ENSIGHT  International Nifedipine-GITS Study: Intervention as a Goal in Hypertensiensin II-increasing drugs, like thiazides or dihydropyridine,
n stroke prevention, compared with ACE inhibitors, as
bserved in the non-black populations of ALLHAT (11,13)
nd the Second Australian National Blood Pressure
iuretics Compared With Placebo or Other Antihypertensive
Comparative Treatments Stroke Outcome
Bendrofluazide vs. placebo and
propranolol vs. placebo
Diuretics reduced stroke rate by 70%.
Beta-blockers reduced stroke rate
by only 27%; this reduction was
non-significant in smokers.
Chlorthalidone vs. placebo Diuretics reduced stroke rate by 36%.
Hydrochlorothiazide/amiloride
vs. placebo and atenolol vs.
placebo
Diuretics reduced stroke rate by 33%.
Beta-blockers reduced stroke by a
non-significant 18%.
Indapamide vs. placebo Diuretics reduced stroke rate by 29%.
Captopril vs. diuretics or beta-
blockers or other
The rate of stroke was higher with
captopril: by 25% in the intention-
to-treat analysis and by 43% in the
on-treatment analysis, whereas
systolic BP was 3 mm Hg higher.
Ramipril vs. placebo Total stroke risk reduction of 32%,
with a 3-mm Hg lower systolic
BP.
Doxazosin vs. chlorthalidone Higher stroke risk of 19% with
doxazosin, with 2-mm Hg higher
systolic BP.
Perindopril vs. placebo and
perindopril plus indapamide
vs. placebo
The rate of stroke was not reduced
by an ACE inhibitor but was
significantly reduced by 43% with
combination therapy of ACE
inhibitor and diuretics.
Candesartan vs. other
antihypertensives
Reduction in nonfatal strokes of 28%
with candesartan, with 3.2/1.6-mm
Hg BP difference.
Lisinoprol vs. chlorthalidone Higher stroke rate of 15% with
lisinopril (p  0.02); no difference
in whites and 30% difference in
blacks.
ering treatment to prevent Heart Attack Trial; BP  blood pressure; CAPPP 
lated systolic hypertension; MRCMedical Research Council; PATS Post-stroke
nt Stroke Study; SCOPE Study on Cognition and Prognosis in the Elderly; SHEP
uretics
parative Treatments Stroke Outcome
ne GITS vs. co-amilozide Total stroke risk was non-significantly
reduced by 10% with nifedipine.
ting diltiazem vs. beta-
rs and/or thiazide
Total stroke risk was significantly reduced
by 20% with diltiazem, despite a 3-mm
Hg higher systolic BP.
ting lacidipine vs.
ol
Total stroke risk was reduced by 36% with
lacidipine; BP reduction was comparable.
lidone vs. amlodipine Non-significant 7% lower stroke risk with
amlodipine for 1-mg higher systolic BP
but 0.8-mm Hg lower diastolic BP.
ting COER-verapamil vs.
e and/or beta-blocker
Relative risk of stroke was 1.5 (95% CI
0.90–1.48) with COER-verapamil.
al; BP  blood pressure; COER  controlled-onset extended-release; CONVINCE
an Lacidipine Study on Atherosclerosis; GITS gastrointestinal therapeutic system;by D
-Up
)
-Low
 iso
ecurred Di
Com
fedipi
ort-ac
locke
ng-ac
tenol
lortha
ng-ac
hiazid
ck Tri
uropeon Treatment; NORDIL  NORdic DILtiazem study.
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Cerebroprotection Mediated by AT2 Receptors April 21, 2004:1343–7ANBP2) study (31), in which the ratio of cardiac events to
trokes was 3.4 and 2.35, respectively.
nifying hypothesis. Our brief review seems to indicate
hat even though they lower BP to a similar extent, not all
ntihypertensive drug classes are equal in their cerebropro-
ective effect. This seems to hold true in hypertensive
atients with a low incidence of coronary artery disease,
uch as in CAPPP, PATS, and PROGRESS. Specifically,
iuretics, calcium antagonists, and ARBs, which increase
ngiotensin II formation (by stimulating renin secretion
hrough sodium depletion [32], sympathetic activation
33,34], or blunting of the negative feedback [32], respec-
ively) seem to have an edge over ACE inhibitors and
eta-blockers, which decrease angiotensin II formation.
he contrast between these drug classes that have an
pposite effect on angiotensin II formation seems to be
articularly important in low-renin populations, such as in
ypertensive African Americans (32), in whom in ALL-
AT (11,13) the stroke risk with lisinopril was 40% higher
han that with chlorthalidone, which is unlikely to be related
o the 4-mm Hg difference in SBP. In their hypothesis,
rown and Brown (1) suggested that the vasoconstrictive
ffect of angiotensin II in the proximal cerebral arteries
ould prevent Charcot-Bouchard aneurysms from ruptur-
ng. However, this AT1 receptor-mediated vasoconstrictive
ffect could only explain prevention of hemorrhagic but not
schemic strokes. To explain the reduction in ischemic
trokes, which are far more prevalent, we further postulate
hat activation of the AT2 receptors by drugs that generate
levated levels of angiotensin II facilitates the recruitment of
ollateral vessels and increases neuronal resistance to anoxia.
xperimental evidence. A non-hemodynamic neuropro-
ective effect mediated by the AT2 receptor was recently
uggested by Dai et al. (35) and Blume et al. (36). They
howed that intracerebral administration of low doses of
rbesartan (not interfering with the systemic effects of
ngiotensin II) before induction of experimental brain
schemia in the rat improved the neurologic outcome (35),
hereas the co-administration of an AT2 receptor blocker
revented such an improvement (36). Furthermore, activa-
ion of the vascular AT2 receptor has been shown to induce
asodilation by local synthesis of nitric oxide and prostacy-
lin (37). Because AT2 receptors are over-expressed in the
schemic brain (38), this mechanism would increase the
ollateral circulation to the insulted regions. In contrast, the
ystemic increase of bradykinin (39) is more likely to
romote vasodilation also to non-ischemic areas, thereby
ossibly leading to a steal syndrome. The significance of
hese hemodynamic mechanisms was demonstrated by two
ndependent teams (40,41) using the experimental model of
cute stroke by carotid ligation in the gerbil. At a compa-
able BP reduction, the gerbils had a lower mortality after
readministration of an ARB than after preadministration
f an ACE inhibitor. However, when an ACE inhibitor was
o-administrated with an ARB, no reduction in mortality
as observed. Furthermore, when angiotensin II was intra-enously infused shortly after carotid ligation, the mortality
f gerbils decreased compared with controls receiving saline
nfusion or an isohypertensive dose of metaraminol (42),
nd this better outcome was associated with a more rapid
artial recovery of ipsilateral cerebral blood flow (43). These
xperimental data indicate that ARBs, at least theoretically,
ffer double protection in that they inhibit the AT1
eceptor-mediated pro-atherothrombotic effects and en-
ance the AT2 receptor-mediated protection against ische-
ia by increasing the generation of angiotensin II. In
ontrast, the benefits of ACE inhibitors in blunting the
T1-mediated pro-atherothrombotic effects might be mit-
gated by reducing circulating angiotensin II levels and
hereby AT2 receptor-dependent cerebroprotection.
onclusions. Recent trials have documented better stroke
rotection with diuretics, calcium antagonists, and ARBs
ompared with ACE inhibitors and beta-blockers. Clinical
nd experimental observations support the concept that this
eduction of strokes may be mediated by AT2 receptors in
mall cerebral arteries. For any given fall in arterial pressure,
rugs that activate these receptors have been shown to be
ore beneficial than drugs that are devoid of such activation
at least in patients with a low incidence of cardiac compli-
ations). As with all hypotheses, the Emmenthal cheese
rinciple applies—it looks good, it smells good, it tastes
ood, but it has large holes! However, stroke is the most
evastating consequence of hypertensive cardiovascular dis-
ase, and its prevention is the foremost goal of antihyper-
ensive therapy. Our hypothesis of cerebroprotection by
T2 receptor activation should be thoroughly tested by a
ead-to-head comparison of an ARB and an ACE inhibitor
n a patient population at high risk of cerebrovascular
isease.
eprint requests and correspondence: Dr. Franz H. Messerli,
chsner Clinic Foundation, 1514 Jefferson Highway, New Or-
eans, Louisiana 70121. E-mail: fmesserli@aol.com.
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